Abstract
Cardiorenal syndrome (CRS) continues to be an area of concern due to the changing understanding of identification, pathophysiology and optimal management. Originally thought that diuretics were always the answer, recent literature has shed lights on the five major CRS subphenotypes, and while conceptual in their classifications, different strategies may be utilized to manage each type. The effect of CRS in pregnant women is largely under discussed and underappreciated as its own entity. Trials involving possible management, specifically utilizing serelaxin, a recombinant form of relaxin, have shown promising results but more data are needed to begin implementing it on a large scale.
Original language | English |
---|---|
Pages (from-to) | 395-399 |
Number of pages | 5 |
Journal | Journal of Clinical Medicine Research |
Volume | 14 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2022 |
Externally published | Yes |
Keywords
- Cardiorenal syndrome
- Pregnant women
- Serelaxin
- Type 5